Proof-of-principal in a preclinical Porcine Model that a Prototype Antimicrobial Blue Light Device Reduces Bacterial Bioburden by >10,000-fold in Heavily MRSA-contaminated Wounds- MHSRS 2024

Negri l, farinelli w, korupolu a, lee h, wang y, hui j, tam j, andy yun s, gelfand j

Abstract accepted for poster presentation at the 2024 Military Health System Research Symposium

We developed an antimicrobial blue light (ABL) device prototype for treating skin wounds, an application for which no approved devices exist. The prototype was tested in a preclinical, in vivo porcine wound model, with partial-thickness wounds heavily infected with methicillin-resistant Staphylococcus aureus (MRSA), the leading antimicrobial resistant (AMR) wound pathogen isolated worldwide.

Our prototype reduced MRSA by 4.7 logs (>99.99%) compared to untreated wounds after only two simple, once-a-day treatments (p<0.0001). These proof-of-principal results suggest ABL could reduce the number of days, doses, and costs of antibiotics for skin wounds, reducing AMR and costs of care. As a stand-alone treatment, or in combination with antimicrobials, these preclinical results support a potential role for our ABL device prototype in treating wound infections.